Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antibody-drug conjugate immunotherapy
- Development stage
- Preclinical
- Lead developer
- Instituto Oncológico Dr Rosell
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Antibody-drug conjugate immunotherapy refers to a developmental therapeutic program by the Instituto Oncologico Dr. Rosell S.L. focused on creating novel antibody-drug conjugates (ADCs) for the treatment of small cell lung cancer (SCLC). This approach involves the use of monoclonal antibodies to selectively deliver potent cytotoxic agents to tumor cells, minimizing systemic toxicity. The program aims to identify and target specific antigens overexpressed in SCLC, such as Delta-like ligand 3 (DLL3) or B7-H3, to improve therapeutic outcomes in a disease characterized by rapid progression and limited treatment options. The integration of ADC technology with immunotherapeutic strategies is intended to enhance the anti-tumor immune response and overcome resistance mechanisms. This program is currently in the preclinical stage of development.
- Other names
- antibody-drug conjugate immunotherapyADC immunotherapy
Beyond the preview
Go deeper on antibody-drug conjugate immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antibody-drug conjugate immunotherapy.